ChipMind

ChipMindChipMind
ChipMind

ChipMind

AI-powered platform for optimizing chip design and verification.

DR 102022Active6Tel Aviv, Israel
Rate

About

ChipMind builds collaborative AI agents that autonomously solve real-world chip design and verification tasks, speeding up development by automating repetitive low-level tasks. Their technology fuses agentic AI with open-source EDA, deeply understanding design, tools, and workflows to seamlessly integrate with human engineers and existing chip development environments. ChipMind serves engineers in the semiconductor industry looking to accelerate their chip development cycles.
Frequently asked

What does ChipMind do?

ChipMind builds collaborative AI agents that autonomously solve real-world chip design and verification tasks, speeding up development by automating repetitive low-level tasks. Their technology fuses agentic AI with open-source EDA, deeply understanding design, tools, and workflows to seamlessly integrate with human engineers and existing chip development environments. ChipMind serves engineers in the semiconductor industry looking to accelerate their chip development cycles.

What is ChipMind's revenue?

StartupHub estimates ChipMind's annual revenue at $1.0M (range $583K to $2.9M, 65% confidence), based on comparable companies in the sector.

What is ChipMind's valuation?

StartupHub estimates ChipMind's effective valuation at $91.2M (range $62.5M to $150.0M, 19% confidence), based on comparable companies in the sector.

How much funding has ChipMind raised?

ChipMind has raised a total of $25M in funding. The most recent round on record is Seed.

Where is ChipMind headquartered?

ChipMind is headquartered in Tel Aviv, Israel.

When was ChipMind founded?

ChipMind was founded in 2022.

What industry does ChipMind operate in?

ChipMind operates in AI Chip, Chip Design, Semiconductor, MLOps, Foundation Model, Generative AI.

How many employees does ChipMind have?

ChipMind has approximately 6 people on record.

HEADCOUNT
6
DOMAIN RATING
10
Comments

No comments yet. Be the first to share your take.